Fast Market Research announces the availability of the new Global Markets Direct report, "Head And Neck Cancer - Pipeline Review, H2 2015", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 02/16/2016 -- Global Markets Direct's, 'Head And Neck Cancer - Pipeline Review, H2 2015', provides an overview of the Head And Neck Cancer's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Get More Details on this Report and a Full Table of Contents at Head And Neck Cancer - Pipeline Review, H2 2015
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
-The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer
-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in the therapeutics development for Head And Neck Cancer and enlists all their major and minor projects
-The report summarizes all the dormant and discontinued pipeline projects
-A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-A detailed assessment of monotherapy and combination therapy pipeline projects
-Coverage of the Head And Neck Cancer pipeline on the basis of target, MoA, route of administration and molecule type
-Latest news and deals relating related to pipeline products
Reasons to Get this Report
-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Develop strategic initiatives by understanding the focus areas of leading companies
-Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer
-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
-Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned in this Report: 4SC AG, AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., Advaxis, Inc., Alchemia Limited, Altor BioScience Corporation, Ambrx, Inc., Amgen Inc., ANP Technologies, Inc., arGEN-X BV, ArQule, Inc., Ascenta Therapeutics, Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals, Inc., Bayer AG, Bexion Pharmaceuticals, LLC., BIND Therapeutics, Inc., Bio-Path Holdings, Inc., BioDiem Ltd, Bionovis SA, Biotest AG, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CEL-SCI Corporation, Celgene Corporation, Cell Medica Limited, Cellceutix Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Centrose LLC, Cristal Therapeutics, Critical Outcome Technologies Inc., CTI BioPharma Corp., CytomX Therapeutics, Inc., Daiichi Sankyo Company, Limited, EcoBiotics Limited, Eisai Co., Ltd., Eli Lilly and Company, EntreChem, S.L., Etubics Corporation, Eureka Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Five Prime Therapeutics, Inc., G&E Herbal Biotechnology Co., Ltd., Genelux Corporation, Genentech, Inc., Genexine, Inc., Genmab A/S, Genticel S.A., GlaxoSmithKline Plc, Gliknik, Inc., Glycotope GmbH, Green Cross Corporation, Hanmi Pharmaceuticals, Co. Ltd., HEC Pharm Co., Ltd., Horizon Pharma Plc, Ignyta, Inc., ImmunoGen, Inc., Immunomedics, Inc., Immunovaccine, Inc., Immunovative Therapies, Ltd., Incyte Corporation, Innate Pharma SA, Inovio Pharmaceuticals, Inc., InteRNA Technologies B.V., IRX Therapeutics, Inc., ISA Pharmaceuticals B.V., ISU ABXIS Co.,Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd., Johnson & Johnson, Karyopharm Therapeutics, Inc., Kite Pharma, Inc., Kolltan Pharmaceuticals, Inc., Laboratoires Pierre Fabre SA, Loxo Oncology, Inc., Lytix Biopharma AS, Mabion SA, Mabtech Limited, MacroGenics, Inc., Marsala Biotech Inc., Meabco A/S, MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Mirati Therapeutics Inc., Molplex Ltd., Multimmune GmbH, NanoCarrier Co., Ltd., Natco Pharma Limited, Northwest Biotherapeutics, Inc., Novartis AG, Omnitura Therapeutics Inc., Oncobiologics, Inc., Oncolys BioPharma Inc., Oncolytics Biotech Inc., Onconova Therapeutics, Inc., OncoSec Medical Inc., Ono Pharmaceutical Co., Ltd., Orbis Biosciences, Inc., Oryx GmbH & Co. KG, Otsuka Holdings Co., Ltd., OXiGENE, Inc., Panacea Biotec Limited, PCI Biotech AS, Pfizer Inc., Pharma Mar, S.A., Pharmacyclics, Inc., Pique Therapeutics, Plexxikon Inc., PNP Therapeutics, Inc., Profectus BioSciences, Inc., Redx Pharma Plc, Sanofi, Sapvax, Sareum Holdings Plc, Selecta Biosciences, Inc., Serina Therapeutics, Inc., Shanghai Henlius Biotech Co., Ltd., Shenzen SiBiono GeneTech Co., Ltd, Shionogi & Co., Ltd., Silence Therapeutics Plc, Sillajen Biotherapeutics, Sinil Pharmaceutical Co., Ltd, Sorrento Therapeutics, Inc., SuviCa Inc., Symphogen A/S, Synta Pharmaceuticals Corp., Taiwan Liposome Company, Ltd., Takara Bio Inc., Takis S.r.l., Teva Pharmaceutical Industries Limited, Theravectys SA, Threshold Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., Vaccibody AS, VasGene Therapeutics, Inc., VentiRx Pharmaceuticals, Inc., Virttu Biologics Limited, Viventia Bio Inc., VLPbio, VM Discovery, Inc., Zhejiang BetaPharma Co., Ltd., Zymeworks Inc., Zyngenia, Inc.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015
-Head And Neck Cancer - Pipeline Review, H1 2015
-Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015
-Cervical Cancer - Pipeline Review, H2 2015
-Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2015